Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Monday October 17 2016, @09:05PM   Printer-friendly
from the no-pain-no-gain? dept.

Scientists at the Institute for Problems of Chemical and Energetic Technologies (IPCET) and collaborators have developed tiovyurtsin, a generic drug for the treatment of pain. The new analgesic lacks the side effects typical of steroid and non-steroidal anti-inflammatory drugs.

"As a raw material for the new drug, we used glyoxal—a substance for which the industrial technology of synthesis was developed by chemists at Tomsk State University," said Sergey Sysolyatin, the director of the IPCET SB RAS (a graduate of TSU's Faculty of Chemistry). "High-energy compounds are also based on glyoxal. At the intermediate stage of synthesis, we are withdrawing a small portion of the substance, modifying it, and then obtaining a drug with excellent pharmacological characteristics."

Preclinical tests carried out at the ED Goldberg Research Institute of Pharmacology and Regenerative Medicine (Tomsk) showed that the new analgesic suppresses pain symptoms of various etiologies and has a longer period of effectiveness than other painkillers, with no toxic effects on the body.

This appears to be an update on research reported in January 2016 in Medical Express: New drug could be safer, non-addictive alternative to morphine, which references an abstract appearing in the journal: Neuropharmacology DOI: 10.1016/j.neuropharm.2015.12.024


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by HiThere on Tuesday October 18 2016, @12:54AM

    by HiThere (866) Subscriber Badge on Tuesday October 18 2016, @12:54AM (#415473) Journal

    When I read the summary I was hoping for something better than Aspirin or Ibuprofen, but the article talks about it as a Morphine substitute. If this works as advertised (they've only got a 28 day study) it could be really important. But that's a big if.

    Think of this as a preliminary lab report. They appear to have done first round human trials and found that usage for a short period revealed no problems within that time period. This is a good start, but clearly insufficient. The next step should be on a *bunch* of moribund patients for a longer period of time. Then perhaps early clinical trials. Then...

    Expect the approval process to take over 5 years, and that's assuming they don't run into any problems.

    P.S.: I am not an expert in the field. If someone who is reads this, please correct me.

    --
    Javascript is what you use to allow unknown third parties to run software you have no idea about on your computer.
    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2